BioSpace News Archive

Dr. Marcus Kostka appointed CEO, Dr. Jörg Vollmer joins as CSO

Approximately 300 Physicians Registered to Attend Axonics-sponsored Seminars Showcasing Recently FDA-Approved1 Axonics r-SNM® System

Vector Smart™ products being presented at 6 vector control conferences in October to prepare for 2020 mosquito season

KSQ Therapeutics to receive non-exclusive access to certain CRISPR IP for its autologous cell therapies, including its existing eTIL™ cell franchise

Tonix Pharmaceuticals Holding Corp. announced that it has joined the Alliance for Biosecurity The Alliance is a coalition of biopharmaceutical companies and laboratory/academic partners that promotes a strong public-private partnership to ensure medical countermeasures are available to protect public health and enhance national health security.

Emerald Health Therapeutics announced that it has notified Pure Sunfarms Corp., its 50%-owned joint venture, that it does not agree that Emerald has any liability under the current Supply Agreement between Emerald and the Joint Venture with respect to the Joint Venture’s recent sales of cannabis to third parties at prices below the predetermined purchase price to Emerald set out in the Supply Agreement.

Anixa Biosciences, Inc., a biotechnology company focused on harnessing the body’s immune system in the fight against cancer, announced the appointment of Thomas Schlumpberger, Ph.D., as Executive Vice President, Diagnostics.

In a prospective study, the addition of RNA genetic testing to hereditary cancer panels identified more disease-causing mutations in patients compared to DNA-only testing and clarified inconclusive results.

First cystic fibrosis (CF) patients with severe exocrine pancreatic insufficiency (EPI) treated in dose escalation study of MS1819-SD in combination with standard porcine pancreatic enzyme replacement therapy (PERT) Patients in study have persistent malnutrition and clinical symptoms of fat malabsorption despite being on the maximum daily doses of PERTs Approximately one-third of CF patients have severe EPI Preliminary data expected in early 2020 NEW YORK, Oct. 15, 2019 (GLOBE NEWS

The company expands its Scientific Advisory Board with four additional RNA splicing, genetics, and disease experts, who join SAB Chair Professor Tyler Jacks & special advisor Professor Phil Sharp as well as several other internationally-recognized SAB members.